The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
Open accessAbstract
CS‐747 is a novel antiplatelet agent that generates an active metabolite, R‐99224, in vivo. CS‐747 itself was totally inactive in vitro. This study examined in vivo pharmacological profiles of CS‐747 after single oral administration to rats. Orally administered CS‐747 (0.3–10 mg kg−1) partially but significantly decreased [3 H]‐2‐methylthio‐ADP binding to rat platelets. CS‐747 (3 mg kg−1, p.o.) treatment neutralized ADP‐induced decreases of cyclic AMP concentrations induced by prostaglandin E 1, suggesting that metabolites of CS‐747 interfere with G i‐linked P2T receptor. CS‐747 (0.3 and 3 mg kg−1, p.o.) markedly inhibited ex vivo washed platelet aggregation in response to ADP but not to thrombin. CS‐747 also exhibited a marked inhibition of ADP‐induced ex vivo platelet aggregation in PRP with a rapid onset (<0.5 h) and long duration (>3 days) of action (ED 50 at 4 h=1.2 mg kg−1). R‐99224 (IC 50=45 μ M) inhibited in vitro PRP aggregation in a concentration‐related manner. CS‐747 prevented thrombus formation in a dose‐related manner with an ED 50 value of 0.68 mg kg−1. CS‐747 was more potent than clopidogrel (6.2 mg kg−1) and ticlopidine (>300 mg kg−1). CS‐747, clopidogrel, and ticlopidine prolonged the bleeding time. The order of potency of these agents in this activity was the same as that in antiaggregatory and antithrombotic activities. These findings indicate that CS‐747 is an orally active and a potent antiplatelet and antithrombotic agent with a rapid onset and long duration of action, and warrants clinical evaluations of the agent. British Journal of Pharmacology (2000) 129, 1439–1446; doi:10.1038/sj.bjp.0703237
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734
Brandt, J. T., Payne, C. D., Wiviott, S. D., Weerakkody, G., Farid, N. A., Small, D. S., Jakubowski, J. A., Naganuma, H., & Winters, K. J. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.010 · Cited by 571
Pharmacological profiles of cloned mammalian P2Y-receptor subtypes
von Kügelgen, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.014 · Cited by 541
Jernberg, T., Payne, C. D., Winters, K. J., Darstein, C., Brandt, J. T., Jakubowski, J. A., Naganuma, H., Siegbahn, A., & Wallentin, L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi877 · Cited by 538
Metadata
- Authors
- Sugidachi, A., Asai, F., Ogawa, T., Inoue, T., & Koike, H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-04
- Volume
- 129
- Issue
- 7
- Pages
- 1439-1446
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1984232159
- Cited by
- 234
- References
- 1
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. https://app.cochat.ai/papers/10.1038/sj.bjp.0703237
- The paper
- Sugidachi, A., Asai, F., Ogawa, T., Inoue, T., & Koike, H. (2000). The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0703237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.